Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies.

ABSTRACT: There is intense interest in developing therapeutic strategies for RAS proteins, the most frequently mutated oncoprotein family in cancer. Development of effective anti-RAS therapies will be aided by the greater appreciation of RAS isoform-specific differences in signaling events that support neoplastic cell growth. However, critical issues that require resolution to facilitate the success of these efforts remain. In particular, the use of well-validated anti-RAS antibodies is essential for accurate interpretation of experimental data. We evaluated 22 commercially available anti-RAS antibodies with a set of distinct reagents and cell lines for their specificity and selectivity in recognizing the intended RAS isoforms and mutants. Reliability varied substantially. For example, we found that

SUBMITTER: Waters AM 

PROVIDER: S-EPMC5812265 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature